RT Journal Article
SR Electronic
T1 Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 1206
OP 1212
DO 10.1124/jpet.104.076877
VO 312
IS 3
A1 James K. Gierse
A1 Yan Zhang
A1 William F. Hood
A1 Mark C. Walker
A1 Jennifer S. Trigg
A1 Timothy J. Maziasz
A1 Carol M. Koboldt
A1 Jerry L. Muhammad
A1 Ben S. Zweifel
A1 Jaime L. Masferrer
A1 Peter C. Isakson
A1 Karen Seibert
YR 2005
UL http://jpet.aspetjournals.org/content/312/3/1206.abstract
AB The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1. Celecoxib and rofecoxib were among the molecules developed from these efforts. We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. Recombinant human COX-1 and COX-2 were used to screen for new highly potent and in vitro selective COX-2 inhibitors and compare kinetic mechanisms of binding and enzyme inhibition with other COX inhibitors. Valdecoxib potently inhibits recombinant COX-2, with an IC50 of 0.005 μM; this compares with IC values of 0.05 μM for celecoxib, 0.5 μM for rofecoxib, and 5 μM for etoricoxib. Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t1/2 ∼98 min). Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC50 = 150 μM). Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of valdecoxib for COX-2. Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC50 = 0.24 μM; COX-1 IC50 = 21.9 μM). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo. In rats, valdecoxib demonstrated marked potency in acute and chronic models of inflammation (air pouch ED50 = 0.06 mg/kg; paw edema ED50 = 5.9 mg/kg; adjuvant arthritis ED50 = 0.03 mg/kg). In these same animals, COX-1 was spared at doses greater than 200 mg/kg. These data provide a basis for the observed potent anti-inflammatory activity of valdecoxib in humans. The American Society for Pharmacology and Experimental Therapeutics